Patent Application
20240316137
The present disclosure relates to the field of medicaments, and particularly to use of Liriodendron chinense (Hemsl.) Sarg. or an extract thereof in the preparation of a medicament for reducing a serum uric acid level and preventing and treating uric acid nephropathy.
Hyperuricemia refers to the condition that. with normal-purine diet, the fasting serum uric acid level measured twice on different days is above 416 μmol/L (7 mg/dl) for men and above 357 μmol/L (6 mg/dl) for women. In recent years, many studies at home and abroad have confirmed that the hyperuricemia is closely related to the occurrence and development of gout, cardiovascular diseases, metabolic syndrome, hypertension, and kidney diseases. The hyperuricemia is an important cause of the increased prevalence rate of Chronic Kidney Disease (CKD) and is an independent risk factor for CKD progression. Studies have shown that reducing of the serum uric acid level can delay the progression of kidney diseases. Preventing and correcting the hyperuricemia, reducing the serum uric acid level, and preventing urate deposition in the kidney are of great importance in the treatment of hyperuricemic nephropathy.
Liriodendron chinense (Hemsl.) Sarg., also known as Chinese Tulip Tree, is a plant belonging to the genus Liriodendron of the family Magnoliaceae. According to the literatures, bark of the Liriodendron chinense (Hemsl.) Sarg. have the effects of dispelling wind and eliminating dampness, relieving a cough, treating rheumatic joint pains and the like. But whether it has the effects of reducing the serum uric acid level and relieving uric acid nephropathy has not yet been reported.
The present disclosure aims to solve at least one of the technical problems existing in the prior art. Therefore, the objective of the present disclosure is to provide use of Liriodendron chinense (Hemsl.) Sarg. or an extract thereof in the preparation of a medicament for reducing a serum uric acid level. Another objective of the present disclosure is to provide use of Liriodendron chinense (Hemsl.) Sarg. or an extract thereof in the preparation of a medicament for treating and/or preventing uric acid nephropathy.
The present disclosure provides use of Liriodendron chinense (Hemsl.) Sarg. or an extract thereof in the preparation of a medicament for reducing a serum uric acid level.
The present disclosure provides use of Liriodendron chinense (Hemsl.) Sarg. or an extract thereof in the preparation of a medicament for treating and/or preventing gout.
The present disclosure provides use of Liriodendron chinense (Hemsl.) Sarg. or an extract thereof in the preparation of a medicament for treating and/or preventing uric acid nephropathy.
Further, the use satisfies at least one of the following:
Further, the medicament promotes renal uric acid excretion.
Further, the medicament is a formulation prepared by using the Liriodendron chinense (Hemsl.) Sarg. or the extract thereof as an active ingredient and adding pharmaceutically acceptable adjuvants or auxiliary ingredients.
Further, the formulation is an oral formulation or an injectable formulation.
Further, a medicinal part of the Liriodendron chinense (Hemsl.) Sarg. is at least one of roots, bark, branches, or leaves.
Further, the extract is an alcohol extract and/or water extract.
Preferably, the alcohol is C1 to C6 fatty alcohol.
Further preferably, the alcohol is ethanol.
Further, the method for preparing the extract includes the following steps: adding the Liriodendron chinense (Hemsl.) Sarg. into an aqueous ethanol solution for extraction, and concentrating the extracting solution, thus obtaining the extract.
Further, the extraction satisfies at least one of the following:
The present disclosure provides Liriodendron chinense (Hemsl.) Sarg. or an extract thereof for reducing a serum uric acid level.
The present disclosure provides Liriodendron chinense (Hemsl.) Sarg. or an extract thereof for treating and/or preventing gout.
The present disclosure provides Liriodendron chinense (Hemsl.) Sarg. or an extract thereof for treating and/or preventing uric acid nephropathy.
The present disclosure provides a method for reducing a serum uric acid level, including administering a subject in need thereof Liriodendron chinense (Hemsl.) Sarg. or an extract thereof for.
The present disclosure provides a method for treating and/or preventing gout, including administering a subject in need thereof Liriodendron chinense (Hemsl.) Sarg. or an extract thereof.
The present disclosure provides a method for treating and/or preventing uric acid nephropathy, including administering a subject in need thereof Liriodendron chinense (Hemsl.) Sarg. or an extract thereof.
The present disclosure provides the use of the Liriodendron chinense (Hemsl.) Sarg. or the extract thereof in the preparation of the medicament for reducing the serum uric acid level and preventing and treating the uric acid nephropathy. Animal experiments have confirmed that the Liriodendron chinense (Hemsl.) Sarg. can significantly reduce the serum uric acid level, and relieve degrees of renal tubular dilation, glomerulosclerosis and renal interstitial fibrosis of hyperuricemic mice. Further research shows that the Liriodendron chinense (Hemsl.) Sarg. plays a role in reducing the serum uric acid level by promoting renal uric acid excretion. The use of the present disclosure can provide a new medicament choice for clinical treatment of hyperuricemia and hyperuricemic nephropathy caused by the hyperuricemia.
The solution of the present disclosure will be explained below in combination with embodiments. Those skilled in the art will understand that the following embodiments are only used to illustrate the present disclosure and should not be construed as limiting the scope of the present disclosure. The contents in the embodiments in which the specific technology or condition are not indicated shall be carried out according to the technology or condition described in the literatures in the art or according to the product specification. The reagents or instruments used without the manufacturer's indication are all conventional products that are commercially available.
Preparation of an extract of Liriodendron chinense (Hemsl.) Sarg.: adding 500 g of the Liriodendron chinense (Hemsl.) Sarg. (including bark, branch, and leaf parts) into 5 L of 75% v/v aqueous ethanol solution, boiling for 3 hours, filtering, and evaporating the solvent to dryness, thus obtaining a brown solid extract.
Experimental methods: male C57BL/6 mice are randomly divided into a normal group, a model group, a positive control group (allopurinol 10 mg/kg/d), a low-dose treatment group (250 mg/kg/d) with the extract of the Liriodendron chinense (Hemsl.) Sarg., and a high-dose treatment group (500 mg/kg/d) with the extract of the Liriodendron chinense (Hemsl.) Sarg., with 6 mice in each group. The mice in the model group and each treatment group are given a gavage of adenine (160 mg/kg/d) and oteracil potassium (2400 mg/kg/d) for model establishing, while the normal group is given a gavage of an equal volume of double distilled water. The model establishing lasts for 3 weeks. During the model establishing, each treatment group is given a gavage of the extract of the Liriodendron chinense (Hemsl.) Sarg. and the allopurinol, and the normal group and the model group are given a gavage of an equal volume of double distilled water. The treatment lasts for 3 weeks. On the 21st day, 24-hour urine of the mice is collected by metabolic cages, and then the mice are sacrificed
Embodiment 1. Effects of Liriodendron chinense (Hemsl.) Sarg. on reducing serum uric acid and preventing and treating uric acid nephropathy
Blood samples of mice are centrifuged for 15 min at 3000 r/min at a room temperature, and then serums are taken for measuring biochemical indicators. Urine samples of the mice are centrifuged for 10 min at 800 g/min at the room temperature, and then upper-layer urine is taken for measuring a level of urine microalbumin. Serum creatinine and Blood Urea Nitrogen (BUN) are detected by using an automatic biochemical analyzer (TC6010L, Jiangxi Tecom Technology Co., Ltd.); and serum uric acid and urine microalbumin are detected by using an automatic biochemical analyzer (BS-240, Shenzhen Mindray Bio-Medical Electronics Co., Ltd.). Experimental results are shown in
As can be seen from
As can be seen from
Embodiment 2. Relieving effect of Liriodendron chinense (Hemsl.) Sarg. on chronic uric acid renal fibrosis
The expression of collagen fibers of kidneys is evaluated by MASSON staining. Meanwhile, α-smooth muscle actin (α-SMA) immunohistochemical staining is conducted on the kidneys. Experimental results are shown in
As can be seen from
As can be seen from
Embodiment 3. Liriodendron chinense (Hemsl.) Sarg. reduces a serum uric acid level by promoting renal uric acid excretion
On the 21st day of the experiment, 24-hour urine of mice is collected by metabolic cages, and urine volumes are recorded. Urine samples of the mice are centrifuged for 10 min at 800 g/min at a room temperature, and then upper-layer urine is taken for measuring a uric acid level in the urine with an automatic biochemical analyzer (BS-240, Shenzhen Mindray Bio-Medical Electronics Co., Ltd.). Uric acid excretion quantity in the 24-hour urine=24-hour urine volume×uric acid concentration in the 24-hour urine. Experimental results are shown in
As can be seen from
The above results show that the Liriodendron chinense (Hemsl.) Sarg. reduces the serum uric acid level by promoting renal uric acid excretion.
| Number | Date | Country | Kind |
|---|---|---|---|
| 201911017671.8 | Oct 2019 | CN | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2020/123257 | 10/23/2020 | WO |
